Failed Back Surgery Syndrome Market

Market Overview:

The 7 major failed back surgery syndrome markets reached a value of US$ 13.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 19.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.

The failed back surgery syndrome market has been comprehensively analyzed in IMARC's new report titled "Failed Back Surgery Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Failed back surgery syndrome (FBSS) is a complex and challenging condition that occurs when an individual experiences persistent or recurring pain following spinal surgery. This ailment is characterized by the failure of surgical interventions to provide adequate relief, leaving patients with ongoing discomfort and limited functionality. The symptoms of FBSS can manifest as chronic pain in the back, legs, or arms, accompanied by numbness, tingling, and muscle weakness. The pain can be stabbing, sharp, or dull, and it often interferes with daily activities, leading to a diminished quality of life. Diagnosing FBSS involves a comprehensive evaluation of the patient's medical history, including details about the initial surgery, the onset and characteristics of the persistent pain, and any attempted treatments post-surgery. Physical examinations, imaging studies, and nerve conduction tests may be used to identify anatomical abnormalities, scar tissue formation, nerve compression, or various other factors contributing to the ongoing pain.

The increasing incidences of inadequate decompression following spinal surgery, which can result in the formation of scar tissue, are primarily driving the failed back surgery syndrome market. In addition to this, the inflating utilization of various therapeutic interventions, such as nerve blocks, spinal cord stimulation, and radiofrequency ablation, aimed at managing chronic pain and restoring functionality, is also creating a positive outlook for the market. Moreover, the widespread adoption of multidisciplinary approaches, including physical therapy, psychological counseling, and rehabilitation programs, to enhance physical well-being and alleviate psychological distress is further bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures, such as endoscopic spinal surgeries and disruptive decompression techniques, which offer potential relief and reduced postoperative complications, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced imaging technologies like MRI and CT scans for accurate diagnosis, coupled with the integration of artificial intelligence in analyzing complex clinical data, is also augmenting the market growth. These developments aid in precise treatment planning and personalized therapeutic approaches, thereby boosting patient outcomes. Furthermore, the escalating application of regenerative medicine strategies, involving stem cell therapies and growth factors, to promote tissue repair and mitigate inflammation in the affected areas is expected to drive the failed back surgery syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the failed back surgery syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for failed back surgery syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the failed back surgery syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the failed back surgery syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the failed back surgery syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current failed back surgery syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the failed back surgery syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the failed back surgery syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the failed back surgery syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of failed back surgery syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of failed back surgery syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of failed back surgery syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with failed back surgery syndrome across the seven major markets?
• What is the size of the failed back surgery syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of failed back surgery syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Failed Back Surgery Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for failed back surgery syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the failed back surgery syndrome market?
• What are the key regulatory events related to the failed back surgery syndrome market?
• What is the structure of clinical trial landscape by status related to the failed back surgery syndrome market?
• What is the structure of clinical trial landscape by phase related to the failed back surgery syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the failed back surgery syndrome market?